A single-site, three-arm, pharmacokinetic Phase I trial of JHL1149 in healthy volunteers

Trial Profile

A single-site, three-arm, pharmacokinetic Phase I trial of JHL1149 in healthy volunteers

Planning
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Colorectal cancer; Lung cancer; Ovarian cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors JHL Biotech
  • Most Recent Events

    • 22 Dec 2017 New trial record
    • 20 Dec 2017 According to a JHL Biotech media release, the company is planning this study in healthy volunteers in Sofia, Bulgaria beginning March 2018.
    • 15 Dec 2017 According to a JHL Biotech media release, the company has submitted a Clinical Trial Application (CTA) to European authorities to initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top